Branded

PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.

The agency announced the approval of Optimer Pharmaceuticals’ Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea, also known as CDAD.

SAN DIEGO — Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.

WESTON, Mass. — Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

WOONSOCKET, R.I. — Many people who provide care and support to loved ones said they are more likely to be nonadherent to their own personal medication regimen than to neglect providing medications to those they are caring for, according to a new study by researchers at Harvard University, Brigham and Women's Hospital and CVS Caremark. Given this, there's a significant opportunity for pharmacists and doctors to identify and work with caregivers to improve medication adherence and chronic disease management.

BRUSSELS — UCB announced that it will add two members to its executive committee, effective July 1.

The drug maker said that Greg Duncan, currently SVP and president of UCB’s North American operations, and Jean-Christophe Tellier, who is joining the company from Ipsen, now are the heads of the U.S. and European commercial operations, respectively.

NEW YORK — Several states are cutting funding to programs that provide HIV medications to people who can’t afford them in an effort to reduce spending, according to a published report.

The Washington Post reported that more than 8,300 people are on waiting lists to obtain antiretrovirals and other drugs that treat HIV, AIDS and related conditions. The Post article highlighted particularly large program cuts in Illinois and Georgia, as well as one proposed for Florida.